Prodrugs in medicinal chemistry and enzyme prodrug therapies

Advanced Drug Delivery Reviews

Volumn 118, Issue , 2017, Pages 65-77

  Walther, Raoul ^a   Rautio, Jarkko ^b   Zelikin, Alexander N ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Drug delivery; Enzyme; Enzyme prodrug therapy; Prodrugs; Self immolative linkers

Indexed keywords

BIOCONVERSION; DRUG DELIVERY; MAMMALS;

ENZYME-PRODRUG THERAPIES; MEDICINAL CHEMISTRY; PHARMACOLOGICAL ACTIVITY; PRODRUGS; RESIDENCE TIME; SELF-IMMOLATIVE; SITE-SPECIFIC; THERAPEUTIC AGENTS;

ENZYMES;

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ACICLOVIR; AMPRENAVIR; BETA GALACTOSIDASE; BETA GLUCOSIDASE; BETA GLUCURONIDASE; BETA LACTAMASE; CHLORAMPHENICOL; CYTOSINE DEAMINASE; DOPAMINE; ETOPOSIDE; FAMCICLOVIR; FLUCYTOSINE; FLUOROURACIL; FOSAMPRENAVIR; FOSPROPOFOL; LEVODOPA; NITROREDUCTASE; PENCICLOVIR; PHENYTOIN; PRODRUG; PROPOFOL; SOFOSBUVIR; TENOFOVIR DISOPROXIL; TERBUTALINE; THYMIDINE KINASE; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIRAL THYMIDINE KINASE;

BIOMEDICAL ENGINEERING; BIOTRANSFORMATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSFORMATION; HUMAN; HYDROLYSIS; HYDROPHILICITY; IC50; IN VITRO STUDY; LIPOPHILICITY; MEDICINAL CHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUSTAINED DRUG RELEASE; ANIMAL; DRUG DESIGN; ENZYME THERAPY; METABOLISM; PROCEDURES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME THERAPY; HUMANS; PRODRUGS;

EID: 85027277403     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2017.06.013     Document Type: Review

References (171)

1. Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Jarvinen, T., Savolainen, J., Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7 (2008), 255–270.
2. Ettmayer, P., Amidon, G.L., Clement, B., Testa, B., Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47 (2004), 2393–2404.
3. Thayer, A.M., Leading drugs under fire in 2015. Chem. Eng. News, 93, 2015, 19.
4. Schywalsky, M., Ihmsen, H., Tzabazis, A., Fechner, J., Burak, E., Vornov, J., Schwilden, H., Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur. J. Anaesthesiol. 20 (2003), 182–190.
5. Glazko, A.J., Edgerton, W.H., Dill, W.A., Lenz, W.R., Chloromycetin palmitate; a synthetic ester of chloromycetin. Antibiot. Chemother. 2 (1952), 234–242.
6. Gatell, J.M., From amprenavir to GW433908. J. HIV Ther. 6 (2001), 95–99.
7. Li, W., Escarpe, P.A., Eisenberg, E.J., Cundy, K.C., Sweet, C., Jakeman, K.J., Merson, J., Lew, W., Williams, M., Zhang, L., Kim, C.U., Bischofberger, N., Chen, M.S., Mendel, D.B., Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42 (1998), 647–653.
8. Sofia, M.J., Bao, D., Chang, W., Du, J., Nagarathnam, D., Rachakonda, S., Reddy, P.G., Ross, B.S., Wang, P., Zhang, H.R., Bansal, S., Espiritu, C., Keilman, M., Lam, A.M., Steuer, H.M., Niu, C., Otto, M.J., Furman, P.A., Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53 (2010), 7202–7218.
9. Bito, L.Z., Baroody, R.A., The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp. Eye Res. 44 (1987), 217–226.
10. Nutt, J.G., Woodward, W.R., Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36 (1986), 739–744.
11. Svensson, L.A., Tunek, A., The design and bioactivation of presystemically stable prodrugs. Drug Metab. Rev. 19 (1988), 165–194.
12. Shimma, N., Umeda, I., Arasaki, M., Murasaki, C., Masubuchi, K., Kohchi, Y., Miwa, M., Ura, M., Sawada, N., Tahara, H., Kuruma, I., Horii, I., Ishitsuka, H., The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg. Med. Chem. 8 (2000), 1697–1706.
13. Varia, S.A., Schuller, S., Sloan, K.B., Stella, V.J., Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73 (1984), 1068–1073.
14. Furfine, E.S., Baker, C.T., Hale, M.R., Reynolds, D.J., Salisbury, J.A., Searle, A.D., Studenberg, S.D., Todd, D., Tung, R.D., Spaltenstein, A., Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48 (2004), 791–798.
15. Perez, O.D., Logg, C.R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., Jolson, D., Amundson, K., Buckley, T., Lohse, D., Lin, A., Burrascano, C., Ibanez, C., Kasahara, N., Gruber, H.E., Jolly, D.J., Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol. Ther. 20 (2012), 1689–1698.
16. Walko, C.M., Lindley, C., Capecitabine: a review. Clin. Ther. 27 (2005), 23–44.
17. Erion, M.D., van Poelje, P.D., Mackenna, D.A., Colby, T.J., Montag, A.C., Fujitaki, J.M., Linemeyer, D.L., Bullough, D.A., Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312 (2005), 554–560.
18. Rautio, J., Laine, K., Prodrugs in drug design and development. Stromgaard, K., Krogsgaard-Larsen, P., Madsen, U., (eds.) Textbook of Drug Design and Discovery, 2017, CRC Press, Boca Raton, 155–173.
19. Guarino, V.R., The molecular design of prodrugs by functional group. Prodrugs and Targeted Delivery, 2010, Wiley-VCH Verlag GmbH & Co. KGaA, 31–60.
20. Prodrugs: Challenges and Rewards. Part 2. 2007, Springer & AAPS Press.
21. Bagshawe, K.D., Sharma, S.K., Springer, C.J., Rogers, G.T., Antibody directed enzyme prodrug therapy (ADEPT): a review of some theoretical, experimental and clinical aspects. Ann. Oncol. 5 (1994), 879–891.
22. Nishiyama, T., Kawamura, Y., Kawamoto, K., Matsumura, H., Yamamoto, N., Ito, T., Ohyama, A., Katsuragi, T., Sakai, T., Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res. 45 (1985), 1753–1761.
23. Sakai, T., Katsuragi, T., Tonomura, K., Nishiyama, T., Kawamura, Y., Implantable encapsulated cytosine deaminase having 5-fluorocytosine-deaminating activity. J. Biotechnol. 2 (1985), 13–21.
24. Mendes, A.C., Zelikin, A.N., Enzyme prodrug therapy engineered into biomaterials. Adv. Funct. Mater., 2014, 5202–5210.
25. Fejerskov, B., Jarlstad Olesen, M.T., Zelikin, A.N., Substrate mediated enzyme prodrug therapy. Adv. Drug Deliv. Rev. 118 (2017), 24–34.
26. Zhang, J., Kale, V., Chen, M., Gene-directed enzyme prodrug therapy. AAPS J. 17 (2015), 102–110.
27. Beaumont, K., Webster, R., Gardner, I., Dack, K., Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 4 (2003), 461–485.
28. Laizure, S.C., Herring, V., Hu, Z.Y., Witbrodt, K., Parker, R.B., The role of human carboxylesterases in drug metabolism: have we overlooked their importance?. Pharmacotherapy 33 (2013), 210–222.
29. Bardsley-Elliot, A., Noble, S., Oseltamivir. Drugs 58 (1999), 851–860 (discussion 861-852).
30. Jarvest, R.L., Sutton, D., Vere Hodge, R.A., Famciclovir. Discovery and development of a novel antiherpesvirus agent. Pharm. Biotechnol. 11 (1998), 313–343.
31. Perry, C.M., Faulds, D., Valaciclovir, a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52 (1996), 754–772.
32. Reusser, P., Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin. Investig. Drugs 10 (2001), 1745–1753.
33. van Rompay, A.R., Johansson, M., Karlsson, A., Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 87 (2000), 189–198.
34. Pradere, U., Garnier-Amblard, E.C., Coats, S.J., Amblard, F., Schinazi, R.F., Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem. Rev. 114 (2014), 9154–9218.
35. Hostetler, K.Y., Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antivir. Res. 82 (2009), A84–A98.
36. Chapman, T., McGavin, J., Noble, S., Tenofovir disoproxil fumarate. Drugs 63 (2003), 1597–1608.
37. McGuigan, C., Pathirana, R.N., Mahmood, N., Devine, K.G., Hay, A.J., Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antivir. Res. 17 (1992), 311–321.
38. McGuigan, C., Hassan-Abdallah, A., Srinivasan, S., Wang, Y., Siddiqui, A., Daluge, S.M., Gudmundsson, K.S., Zhou, H., McLean, E.W., Peckham, J.P., Burnette, T.C., Marr, H., Hazen, R., Condreay, L.D., Johnson, L., Balzarini, J., Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. J. Med. Chem. 49 (2006), 7215–7226.
39. Cahard, D., McGuigan, C., Balzarini, J., Aryloxy phosphoramidate triesters as pro-tides. Mini-Rev. Med. Chem. 4 (2004), 371–381.
40. De Clercq, E., Li, G., Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29 (2016), 695–747.
41. Gentile, I., Maraolo, A.E., Buonomo, A.R., Zappulo, E., Borgia, G., The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin. Drug Discovery 10 (2015), 1363–1377.
42. Birkus, G., Wang, R., Liu, X., Kutty, N., MacArthur, H., Cihlar, T., Gibbs, C., Swaminathan, S., Lee, W., McDermott, M., Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob. Agents Chemother. 51 (2007), 543–550.
43. Stella, V.J., Nti-Addae, K.W., Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 59 (2007), 677–694.
44. Wire, M.B., Shelton, M.J., Studenberg, S., Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45 (2006), 137–168.
45. Mitchell, L.A., Lopez Espinoza, F., Mendoza, D., Kato, Y., Inagaki, A., Hiraoka, K., Kasahara, N., Gruber, H.E., Jolly, D.J., Robbins, J.M., Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. J. Neuro-Oncol., 2017 http://dx.doi.org/10.1093/neuonc/nox037.
46. Senter, P.D., Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4 (1990), 188–193.
47. Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, F., Bisset, G.M.F., Jarman, M., Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33 (1990), 677–681.
48. Tietze, L.F., von Hof, J.M., Müller, M., Krewer, B., Schuberth, I., Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer. Angew. Chem. Int. Ed. 49 (2010), 7336–7339.
49. Fillat, C., Carrio, M., Cascante, A., Sangro, B., Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr. Gene Ther. 3 (2003), 13–26.
50. Shepherd, T.A., Jungheim, L.N., Meyer, D.L., Starling, J.J., A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett. 1 (1991), 21–26.
51. Jungheim, L.N., Shepherd, T.A., Kling, J.K., Synthesis of a cephalosporin-doxorubicin antitumor prodrug: a substrate for an antibody-targeted enzyme. Heterocycles 35 (1993), 339–348.
52. Vrudhula, V.M., Svensson, H.P., Senter, P.D., Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody β-lactamase conjugates. J. Med. Chem. 40 (1997), 2788–2792.
53. Rodrigues, M.L., Carter, P., Wirth, C., Mullins, S., Lee, A., Blackburn, B.K., Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol. 2 (1995), 223–227.
54. Alexander, R.P., Beeley, N.R.A., O'Driscoll, M., O'Neill, F.P., Millican, T.A., Pratt, A.J., Willenbrock, F.W., Cephalosporin nitrogen mustard carbamate prodrugs for “ADEPT”. Tetrahedron Lett. 32 (1991), 3269–3272.
55. Alexander, J., Cargill, R., Michelson, S.R., Schwam, H., (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem. 31 (1988), 318–322.
56. Jungheim, L.N., Shepherd, T.A., Design of antitumor prodrugs: substrates for antibody targeted enzymes. Chem. Rev. 94 (1994), 1553–1566.
57. Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M., Senter, P.D., Monoclonal antibody-.beta.-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug. Chem. 3 (1992), 176–181.
58. Svensson, H.P., Wallace, P.M., Senter, P.D., Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates. Bioconjug. Chem. 5 (1994), 262–267.
59. Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Senter, P.D., Wallace, P.M., Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-.beta.-lactamase conjugates. Bioconjug. Chem. 4 (1993), 334–340.
60. Williams, Elsie M., Little, Rory F., Mowday, Alexandra M., Rich, Michelle H., Chan-Hyams, Jasmine V.E., Copp, Janine N., Smaill, Jeff B., Patterson, Adam V., Ackerley, David F., Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility. Biochem. J. 471 (2015), 131–153.
61. Mauger, A.B., Burke, P.J., Somani, H.H., Friedlos, F., Knox, R.J., Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37 (1994), 3452–3458.
62. Hay, M.P., Sykes, B.M., Denny, W.A., O'Connor, C.J., Substituent effects on the kinetics of reductively-initiated fragmentation of nitrobenzyl carbamates designed as triggers for bioreductive prodrugs. J. Chem. Soc. Perkin Trans. 1 (1999), 2759–2770.
63. Hay, M.P., Wilson, W.R., Denny, W.A., Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg. Med. Chem. Lett. 9 (1999), 3417–3422.
64. Anlezark, G.M., Melton, R.G., Sherwood, R.F., Wilson, W.R., Denny, W.A., Palmer, B.D., Knox, R.J., Friedlos, F., Williams, A., Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 50 (1995), 609–618.
65. Hay, M.P., Wilson, W.R., Denny, W.A., Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. Bioorg. Med. Chem. 13 (2005), 4043–4055.
66. Zhang, Z., Tanabe, K., Hatta, H., Nishimoto, S.-i., Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity. Org. Biomol. Chem. 3 (2005), 1905–1910.
67. Sharma, K., Sengupta, K., Chakrapani, H., Nitroreductase-activated nitric oxide (NO) prodrugs. Bioorg. Med. Chem. Lett. 23 (2013), 5964–5967.
68. Shi, Y., Zhang, S., Zhang, X., A novel near-infrared fluorescent probe for selectively sensing nitroreductase (NTR) in an aqueous medium. Analyst 138 (2013), 1952–1955.
69. Saneyoshi, H., Hiyoshi, Y., Iketani, K., Kondo, K., Ono, A., Bioreductive deprotection of 4-nitrobenzyl group on thymine base in oligonucleotides for the activation of duplex formation. Bioorg. Med. Chem. Lett. 25 (2015), 5632–5635.
70. Sammet, B., 4-Nitrophenyl chloroformate: a versatile coupling reagent. Synlett 2009 (2009), 3050–3051.
71. Tukey, R.H., Strassburg, C.P., Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40 (2000), 581–616.
72. Cheng, T.L., Chou, W.C., Chen, B.M., Chern, J.W., Roffler, S.R., Characterization of an antineoplastic glucuronide prodrug. Biochem. Pharmacol. 58 (1999), 325–328.
73. Weyel, D., Sedlacek, H.-H., Müller, R., Brüsselbach, S., Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7 (2000), 224–231.
74. Connors, T.A., Whisson, M.E., Cure of mice bearing advanced plasma cell tumours with aniline mustard : the relationship between glucuronidase activity and tumour sensitivity. Nature 210 (1966), 866–867.
75. Chen, K.-C., Wu, S.-Y., Leu, Y.-L., Prijovich, Z.M., Chen, B.-M., Wang, H.-E., Cheng, T.-L., Roffler, S.R., A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment. Bioconjug. Chem. 22 (2011), 938–948.
76. de Graaf, M., Boven, E., Oosterhoff, D., van der Meulen-Muileman, I.H., Huls, G.A., Gerritsen, W.R., Haisma, H.J., Pinedo, H.M., A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br. J. Cancer 86 (2002), 811–818.
77. Chen, K.C., Cheng, T.L., Leu, Y.L., Prijovich, Z.M., Chuang, C.H., Chen, B.M., Roffler, S.R., Membrane-localized activation of glucuronide prodrugs by [beta]-glucuronidase enzymes. Cancer Gene Ther. 14 (2006), 187–200.
78. Haisma, H.J., van Muijen, M., Pinedo, H.M., Boven, E., Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys. 24 (1994), 185–192.
79. Stachulski, A.V., Jenkins, G.N., The synthesis of O-glucuronides. Nat. Prod. Rep. 15 (1998), 173–186.
80. Stachulski, A.V., Meng, X., Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides. Nat. Prod. Rep. 30 (2013), 806–848.
81. Tranoy-Opalinski, I., Legigan, T., Barat, R., Clarhaut, J., Thomas, M., Renoux, B., Papot, S., β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur. J. Med. Chem. 74 (2014), 302–313.
82. Paulsen, H., Advances in selective chemical syntheses of complex oligosaccharides. Angew. Chem. Int. Ed. 21 (1982), 155–173.
83. Chen, K.-C., Schmuck, K., Tietze, L.F., Roffler, S.R., Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol. Pharm. 10 (2013), 1773–1782.
84. Wang, S.-M., Chern, J.-W., Yeh, M.-Y., Ng, J.C., Tung, E., Roffler, S.R., Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52 (1992), 4484–4491.
85. Tietze, L.F., Feuerstein, T., Enzyme and proton-activated prodrugs for a selective cancer therapy. Curr. Pharm. Des. 9 (2003), 2155–2175.
86. Lutz, F.T., Kianga, S., Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Curr. Pharm. Des. 17 (2011), 3527–3547.
87. de Graaf, M., Pinedo, H.M., Quadir, R., Haisma, H.J., Boven, E., Cytosolic β-glycosidases for activation of glycoside prodrugs of daunorubicin. Biochem. Pharmacol. 65 (2003), 1875–1881.
88. Houba, P.H.J., Leenders, R.G.G., Boven, E., Scheeren, J.W., Pinedo, H.M., Haisma, H.J., Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem. Pharmacol. 52 (1996), 455–463.
89. Calvaresi, E.C., Hergenrother, P.J., Glucose conjugation for the specific targeting and treatment of cancer. Chem. Sci. 4 (2013), 2319–2333.
90. Lin, Y.-S., Tungpradit, R., Sinchaikul, S., An, F.-M., Liu, D.-Z., Phutrakul, S., Chen, S.-T., Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. J. Med. Chem. 51 (2008), 7428–7441.
91. Liu, D.-Z., Sinchaikul, S., Reddy, P.V.G., Chang, M.-Y., Chen, S.-T., Synthesis of 2′-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells. Bioorg. Med. Chem. Lett. 17 (2007), 617–620.
92. Mikuni, K., Nakanishi, K., Hara, K., Hara, K., Iwatani, W., Amano, T., Nakamura, K., Tsuchiya, Y., Okumoto, H., Mandai, T., In vivo antitumor activity of novel water-soluble Taxoids. Biol. Pharm. Bull. 31 (2008), 1155–1158.
93. Tietze, L.F., Krewer, B., Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem. Biol. Drug Des. 74 (2009), 205–211.
94. Andrianomenjanahary, S., Dong, X., Florent, J.C., Gaudel, G., Gesson, J.P., Jacquesy, J.C., Koch, M., Michel, S., Mondon, M., Monneret, C., Petit, P., Renoux, B., Tillequin, F., Synthesis of novel targeted pro-prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate (part 1). Bioorg. Med. Chem. Lett. 2 (1992), 1093–1096.
95. Leenders, R.G.G., Damen, E.W.P., Bijsterveld, E.J.A., Scheeren, H.W., Houba, P.H.J., van der Meulen-Muileman, I.H., Boven, E., Haisma, H.J., Novel anthracycline-spacer-β-glucuronide, -β-glucoside, and –β-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. 7 (1999), 1597–1610.
96. Thomas, M., Clarhaut, J., Strale, P.-O., Tranoy-Opalinski, I., Roche, J., Papot, S., A galactosidase-responsive “Trojan horse” for the selective targeting of folate receptor-positive tumor cells. ChemMedChem 6 (2011), 1006–1010.
97. Ghosh, A.K., Khan, S., Marini, F., Nelson, J.A., Farquhar, D., A daunorubicin β-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapy. Tetrahedron Lett. 41 (2000), 4871–4874.
98. Adidala, R., Devalapally, H., Srivari, C., Devarakonda R, K., Raghuram Rao, A., An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation. Drug Dev. Ind. Pharm. 38 (2012), 1047–1053.
99. Oliveri, V., Giuffrida, M.L., Vecchio, G., Aiello, C., Viale, M., Gluconjugates of 8-hydroxyquinolines as potential anti-cancer prodrugs. Dalton Trans. 41 (2012), 4530–4535.
100. Kamal, A., Tekumalla, V., Krishnan, A., Pal-Bhadra, M., Bhadra, U., Development of pyrrolo[2,1-c][1,4]benzodiazepine β-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT. ChemMedChem 3 (2008), 794–802.
101. Valdez, C.A., Saavedra, J.E., Showalter, B.M., Davies, K.M., Wilde, T.C., Citro, M.L., Barchi, J.J., Deschamps, J.R., Parrish, D., El-Gayar, S., Schleicher, U., Bogdan, C., Keefer, L.K., Hydrolytic reactivity trends among potential prodrugs of the O2-glycosylated diazeniumdiolate family. Targeting nitric oxide to macrophages for antileishmanial activity. J. Med. Chem. 51 (2008), 3961–3970.
102. Cai, T.B., Lu, D., Tang, X., Zhang, Y., Landerholm, M., Wang, P.G., New glycosidase activated nitric oxide donors: glycose and 3-morphorlinosydnonimine conjugates. J. Organomet. Chem. 70 (2005), 3518–3524.
103. Abraham, R., Aman, N., von Borstel, R., Darsley, M., Kamireddy, B., Kenten, J., Morris, G., Titmas, R., Conjugates of COL-1 monoclonal antibody and β-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug β-D-galactosyl-5-fluorouridine. Cell Biophys. 24 (1994), 127–133.
104. Janin, Y.L., Zoltobroda, G., Huel, C., Monneret, C., Synthesis of chloramphenicol and mandelonitrile galactose-containing prodrugs. J. Carbohydr. Chem. 21 (2002), 275–286.
105. Mamber, S.W., Mikkilineni, A.B., Pack, E.J., Rosser, M.P., Wong, H., Ueda, Y., Forenza, S., Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase. J. Pharmacol. Exp. Ther. 274 (1995), 877–883.
106. Kratz, F., Müller, I.A., Ryppa, C., Warnecke, A., Prodrug strategies in anticancer chemotherapy. ChemMedChem 3 (2008), 20–53.
107. Cain, B.F., 2-Acyloxymethylbenzoic acids. Novel amine protective functions providing amides with the lability of esters. J. Organomet. Chem. 41 (1976), 2029–2031.
108. Sinkula, A.A., Yalkowsky, S.H., Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci. 64 (1975), 181–210.
109. Carl, P.L., Chakravarty, P.K., Katzenellenbogen, J.A., A novel connector linkage applicable in prodrug design. J. Med. Chem. 24 (1981), 479–480.
110. Kolakowski, R.V., Haelsig, K.T., Emmerton, K.K., Leiske, C.I., Miyamoto, J.B., Cochran, J.H., Lyon, R.P., Senter, P.D., Jeffrey, S.C., The methylene alkoxy carbamate self-immolative unit: utilization for the targeted delivery of alcohol-containing payloads with antibody–drug conjugates. Angew. Chem. Int. Ed. 55 (2016), 7948–7951.
111. Staben, L.R., Koenig, S.G., Lehar, S.M., Vandlen, R., Zhang, D., Chuh, J., Yu, S.-F., Ng, C., Guo, J., Liu, Y., Fourie-O'Donohue, A., Go, M., Linghu, X., Segraves, N.L., Wang, T., Chen, J., Wei, B., Phillips, G.D.L., Xu, K., Kozak, K.R., Mariathasan, S., Flygare, J.A., Pillow, T.H., Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates. Nat. Chem., 2016 (advance online publication).
112. Sun, T., Morger, A., Castagner, B., Leroux, J.-C., An oral redox-sensitive self-immolating prodrug strategy. Chem. Commun. 51 (2015), 5721–5724.
113. Alouane, A., Labruère, R., Le Saux, T., Schmidt, F., Jullien, L., Self-immolative spacers: kinetic aspects, structure–property relationships, and applications. Angew. Chem. Int. Ed. 54 (2015), 7492–7509.
114. Blencowe, C.A., Russell, A.T., Greco, F., Hayes, W., Thornthwaite, D.W., Self-immolative linkers in polymeric delivery systems. Polym. Chem. 2 (2011), 773–790.
115. Kock, A., Zuwala, K., Smith, A.A.A., Ruiz-Sanchis, P., Wohl, B.M., Tolstrup, M., Zelikin, A.N., Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs. Chem. Commun. 50 (2014), 14498–14500.
116. Ruiz-Sanchis, P., Wohl, B.M., Smith, A.A.A., Zuwala, K., Melchjorsen, J., Tolstrup, M., Zelikin, A.N., Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells. Adv. Healthc. Mater. 4 (2015), 65–68.
117. Riber, C.F., Smith, A.A.A., Zelikin, A.N., Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs. Adv. Healthc. Mater. 4 (2015), 1887–1890.
118. Papot, S., Tranoy, I., Tillequin, F., Florent, J., Gesson, J., Design of selectively activated anticancer prodrugs: elimination and cyclization strategies. Curr. Med. Chem. Anticancer Agents 2 (2002), 155–185.
119. Tranoy-Opalinski, I., Fernandes, A., Thomas, M., Gesson, J.P., Papot, S., Design of self-immolative linkers for tumour-activated prodrug therapy. Anti Cancer Agents Med. Chem. 8 (2008), 618–637.
120. Florent, J.-C., Dong, X., Gaudel, G., Mitaku, S., Monneret, C., Gesson, J.-P., Jacquesy, J.-C., Mondon, M., Renoux, B., Andrianomenjanahary, S., Michel, S., Koch, M., Tillequin, F., Gerken, M., Czech, J., Straub, R., Bosslet, K., Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 41 (1998), 3572–3581.
121. Houba, P.H.J., Boven, E., Meulen-Muileman, I.H.V.D., Leenders, R.G.G., Scheeren, J.W., Pinedo, H.M., Haisma, H.J., A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br. J. Cancer 84 (2001), 550–557.
122. de Graaf, M., Nevalainen, T.J., Scheeren, H.W., Pinedo, H.M., Haisma, H.J., Boven, E., A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochem. Pharmacol. 68 (2004), 2273–2281.
123. Grinda, M., Clarhaut, J., Tranoy-Opalinski, I., Renoux, B., Monvoisin, A., Cronier, L., Papot, S., A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier. ChemMedChem 6 (2011), 2137–2141.
124. Legigan, T., Clarhaut, J., Renoux, B., Tranoy-Opalinski, I., Monvoisin, A., Jayle, C., Alsarraf, J., Thomas, M., Papot, S., Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy. Eur. J. Med. Chem. 67 (2013), 75–80.
125. Bouvier, E., Thirot, S., Schmidt, F., Monneret, C., A new paclitaxel prodrug for use in ADEPT strategy. Org. Biomol. Chem. 1 (2003), 3343–3352.
126. Schmidt, F., Ungureanu, I., Duval, R., Pompon, A., Monneret, C., Cancer chemotherapy: a paclitaxel prodrug for ADEPT (antibody-directed enzyme prodrug therapy). Eur. J. Org. Chem. 2001 (2001), 2129–2134.
127. El Alaoui, A., Schmidt, F., Monneret, C., Florent, J.-C., Protecting groups for glucuronic acid: application to the synthesis of new paclitaxel (Taxol) derivatives. J. Organomet. Chem. 71 (2006), 9628–9636.
128. El Alaoui, A., Saha, N., Schmidt, F., Monneret, C., Florent, J.C., New Taxol (R) (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem. 14 (2006), 5012–5019.
129. Leu, Y.-L., Roffler, S.R., Chern, J.-W., Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. 42 (1999), 3623–3628.
130. Leu, Y.-L., Chen, C.-S., Wu, Y.-J., Chern, J.-W., Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J. Med. Chem. 51 (2008), 1740–1746.
131. Prijovich, Z.M., Burnouf, P.-A., Chou, H.-C., Huang, P.-T., Chen, K.-C., Cheng, T.-L., Leu, Y.-L., Roffler, S.R., Synthesis and antitumor properties of BQC-glucuronide, a camptothecin prodrug for selective tumor activation. Mol. Pharm. 13 (2016), 1242–1250.
132. Angenault, S., Thirot, S., Schmidt, F., Monneret, C., Pfeiffer, B., Renard, P., Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (prodrug monoTherapy) strategy. Bioorg. Med. Chem. Lett. 13 (2003), 947–950.
133. Jourden, J.L.M., Daniel, K.B., Cohen, S.M., Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors. Chem. Commun. 47 (2011), 7968–7970.
134. Toki, B.E., Cerveny, C.G., Wahl, A.F., Senter, P.D., Protease-mediated fragmentation of p-Amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Organomet. Chem. 67 (2002), 1866–1872.
135. Lee, H.Y., Jiang, X., Lee, D., Kinetics of self-immolation: faster signal relay over a longer linear distance?. Org. Lett. 11 (2009), 2065–2068.
136. Schmid, K.M., Jensen, L., Phillips, S.T., A self-immolative spacer that enables tunable controlled release of phenols under neutral conditions. J. Organomet. Chem. 77 (2012), 4363–4374.
137. Meyer, Y., Richard, J.-A., Delest, B., Noack, P., Renard, P.-Y., Romieu, A., A comparative study of the self-immolation of para-aminobenzylalcohol and hemithioaminal-based linkers in the context of protease-sensitive fluorogenic probes. Org. Biomol. Chem. 8 (2010), 1777–1780.
138. Saari, W.S., Schwering, J.E., Lyle, P.A., Smith, S.J., Engelhardt, E.L., Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole. J. Med. Chem. 33 (1990), 97–101.
139. de Groot, F.M.H., Loos, W.J., Koekkoek, R., van Berkom, L.W.A., Busscher, G.F., Seelen, A.E., Albrecht, C., de Bruijn, P., Scheeren, H.W., Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J. Organomet. Chem. 66 (2001), 8815–8830.
140. Levine, M.N., Raines, R.T., Trimethyl lock: a trigger for molecular release in chemistry, biology, and pharmacology. Chem. Sci. 3 (2012), 2412–2420.
141. Amsberry, K.L., Borchardt, R.T., The lactonization of 2′-hydroxyhydrocinnamic acid amides: a potential prodrug for amines. J. Organomet. Chem. 55 (1990), 5867–5877.
142. Carpino, L.A., Triolo, S.A., Berglund, R.A., Reductive lactonization of strategically methylated quinone propionic acid esters and amides. J. Organomet. Chem. 54 (1989), 3303–3310.
143. Amsberry, K.L., Borchardt, R.T., Amine prodrugs which utilize hydroxy amide lactonization. I. A potential redox-sensitive amide prodrug. Pharm. Res. 8 (1991), 323–330.
144. Amsberry, K.L., Gerstenberger, A.E., Borchardt, R.T., Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug. Pharm. Res. 8 (1991), 455–461.
145. Senter, P.D., Pearce, W.E., Greenfield, R.S., Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J. Organomet. Chem. 55 (1990), 2975–2978.
146. Nicolaou, M.G., Yuan, C.-S., Borchardt, R.T., Phosphate prodrugs for amines utilizing a fast intramolecular hydroxy amide lactonization. J. Organomet. Chem. 61 (1996), 8636–8641.
147. Nam, N.-H., Kim, Y., You, Y.-J., Hong, D.-H., Kim, H.-M., Ahn, B.-Z., Water soluble prodrugs of the antitumor agent 3-[(3-amino-4-methoxy)phenyl]-2-(3,4,5-trimethoxyphenyl)cyclopent-2-ene-1-one. Bioorg. Med. Chem. 11 (2003), 1021–1029.
148. Sockolosky, J.T., Szoka, F.C., The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv. Drug Deliv. Rev. 91 (2015), 109–124.
149. Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L.B., McGuire, J., Steensgaard, D.B., Strauss, H.M., Gram, D.X., Knudsen, S.M., Nielsen, F.S., Thygesen, P., Reedtz-Runge, S., Kruse, T., Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58 (2015), 7370–7380.
150. Drucker, D.J., Dritselis, A., Kirkpatrick, P., Liraglutide. Nat. Rev. Drug Discov. 9 (2010), 267–268.
151. Liu, H., Moynihan, K.D., Zheng, Y., Szeto, G.L., Li, A.V., Huang, B., Van Egeren, D.S., Park, C., Irvine, D.J., Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507 (2014), 519–522.
152. Elsadek, B., Kratz, F., Impact of albumin on drug delivery — new applications on the horizon. J. Control. Release 157 (2012), 4–28.
153. Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132 (2008), 171–183.
154. Kratz, F., A clinical update of using albumin as a drug vehicle — a commentary. J. Control. Release 190 (2014), 331–336.
155. Senter, P.D., Sievers, E.L., The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30 (2012), 631–637.
156. Kratz, F., Mansour, A., Soltau, J., Warnecke, A., Fichtner, I., Unger, C., Drevs, J., Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch. Pharm. 338 (2005), 462–472.
157. Elsadek, B., Graeser, R., Warnecke, A., Unger, C., Saleem, T., El-Melegy, N., Madkor, H., Kratz, F., Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen. Med. Chem. Lett. 1 (2010), 234–238.
158. Graeser, R., Chung, D.-E., Esser, N., Moor, S., Schächtele, C., Unger, C., Kratz, F., Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int. J. Cancer 122 (2008), 1145–1154.
159. Chung, D.-E., Kratz, F., Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 16 (2006), 5157–5163.
160. Mansour, A.M., Drevs, J., Esser, N., Hamada, F.M., Badary, O.A., Unger, C., Fichtner, I., Kratz, F., A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63 (2003), 4062–4066.
161. Chung, S.W., Choi, J.U., Lee, B.S., Byun, J., Jeon, O.-C., Kim, S.W., Kim, I.-S., Kim, S.Y., Byun, Y., Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor. Biomaterials 94 (2016), 1–8.
162. Jeffrey, S.C., Andreyka, J.B., Bernhardt, S.X., Kissler, K.M., Kline, T., Lenox, J.S., Moser, R.F., Nguyen, M.T., Okeley, N.M., Stone, I.J., Zhang, X., Senter, P.D., Development and properties of β-glucuronide linkers for monoclonal antibody − drug conjugates. Bioconjug. Chem. 17 (2006), 831–840.
163. Warnecke, A., Fichtner, I., Saß G., Kratz, F., Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch. Pharm. 340 (2007), 389–395.
164. Zhao, D., Zhang, H., Tao, W., Wei, W., Sun, J., He, Z., A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity. Biomater. Sci. 5 (2017), 502–510.
165. Legigan, T., Clarhaut, J., Renoux, B., Tranoy-Opalinski, I., Monvoisin, A., Berjeaud, J.-M., Guilhot, F., Papot, S., Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. J. Med. Chem. 55 (2012), 4516–4520.
166. Renoux, B., Raes, F., Legigan, T., Peraudeau, E., Eddhif, B., Poinot, P., Tranoy-Opalinski, I., Alsarraf, J., Koniev, O., Kolodych, S., Lerondel, S., Le Pape, A., Clarhaut, J., Papot, S., Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chem. Sci. 8 (2017), 3427–3433.
167. Sahin, U., Hartmann, F., Senter, P., Pohl, C., Engert, A., Diehl, V., Pfreundschuh, M., Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50 (1990), 6944–6948.
168. Senter, P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A., Hellström, K.E., Hellström, I., Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49 (1989), 5789–5792.
169. Hu, L., Yu, C., Jiang, Y., Han, J., Li, Z., Browne, P., Race, P.R., Knox, R.J., Searle, P.F., Hyde, E.I., Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J. Med. Chem. 46 (2003), 4818–4821.
170. Tietze, L.F., Schuster, H.J., Krewer, B., Schuberth, I., Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy. J. Med. Chem. 52 (2009), 537–543.
171. Legigan, T., Clarhaut, J., Tranoy-Opalinski, I., Monvoisin, A., Renoux, B., Thomas, M., Le Pape, A., Lerondel, S., Papot, S., The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. Angew. Chem. Int. Ed. 51 (2012), 11606–11610.